3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
5
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colonic Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Magnetic Resonance Spectroscopy
17
Iodine-131
16
lenvatinib
13
trametinib
12
Thyrotropin Alfa
11
Sorafenib
11
pembrolizumab
10
dabrafenib
10
Paclitaxel
9
vandetanib
8
Thyroxine
8
Surgical Procedures, Operative
7
Sunitinib
7
selpercatinib
6
cabozantinib
6
Nivolumab
6
Fluorodeoxyglucose F18
6
Everolimus
6
pazopanib
5
Vemurafenib
5
Thyroidectomy
5
Specimen Handling
5
Saline Solution
5
Radiotherapy
5
Radiofrequency Ablation
5
Cyclophosphamide
5
Cisplatin
5
Biopsy
5
apatinib
4
anlotinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Neoplasms
×
naporafenib
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled